Prognostic value of nuclear hepatoma-derived growth factor (HDGF) localization in patients with breast cancer

Pathology Research and Practice

Volumn 208, Issue 8, 2012, Pages 437-443

  Chen, Xiaoyan ^a   Yun, Jun ^a   Fei, Fei ^b   Yi, Jun ^a   Tian, Ruifeng ^a   Li, Sanzhong ^a   Gan, Xiaoqiang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Hepatoma derived growth factor; Prognosis; Recurrence; Survival

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; KI 67 ANTIGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

ADENOCARCINOMA; BREAST NEOPLASMS; CELL NUCLEUS; CHINA; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 84864100619     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.03.004     Document Type: Article

References (28)

1. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-187.
2. Cilley R.E., Zgleszewski S.E., Chinoy M.R. Fetal lung development: airway pressure enhances the expression of developmental genes. J. Pediatr. Surg. 2000, 35:113-118.
3. Contesso G., Mouriesse H., Friedman S., Genin J., Sarrazin D., Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1010 patients, uniformly treated at the Institut Gustave-Roussy. J. Clin. Oncol. 1987, 5:1378-1386.
4. Donegan W.L. Prognostic factors. Stage and receptor status in breast cancer. Cancer 1992, 70:1755-1764.
5. Donegan W.L. Tumor-related prognostic factors for breast cancer. CA - Cancer J. Clin. 1997, 47:28-51.
6. Elston E.W., Ellis I.O. Method for grading breast cancer. J. Clin. Pathol. 1993, 46:189-190.
7. Enomoto H., Yoshida K., Kishima Y., et al. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002, 36:1519-1527.
8. Everett A.D., Lobe D.R., Matsumura M.E., Nakamura H., McNamara C.A. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. Clin. Invest. 2000, 105:567-575.
9. Everett A.D., Stoops T., McNamara C.A. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. Biol. Chem. 2001, 276:37564-37568.
10. Guo Z., He Y., Wang S., Zhang A., Zhao P., Gao C., Cao B. Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells. Oncol. Rep. 2011, 26:511-517.
11. Howell A., Evans G.D. Hormone replacement therapy and breast cancer. Recent results. Cancer Res. 2011, 188:115-124.
12. Hu T.H., Huang C.C., Liu L.F., et al. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 2003, 98:1444-1456.
13. Iwasaki T., Nakagawa K., Nakamura H., Takada Y., Matsui K., Kawahara K. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncol. Rep. 2005, 13:1075-1080.
14. Kim S.S., Klemp J., Fabian C. Breast cancer and fertility preservation. Fertil. Steril. 2011, 95:1535-1543.
15. Kishima Y., Yamamoto H., Izumoto Y., et al. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J. Biol. Chem. 2002, 277:10315-10322.
16. Makhoul I., Kiwan E. Neoadjuvant systemic treatment of breast cancer. J. Surg. Oncol. 2011, 103:348-357.
17. Margenthaler J.A. Optimizing conservative breast surgery. J. Surg. Oncol. 2011, 103:306-312.
18. Nakamura H., Kambe H., Egawa T., et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin. Chim. Acta 1989, 183:273-284.
19. Nakamura H., Izumoto Y., Kambe H., et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J. Biol. Chem. 1994, 269:25143-25149.
20. Okuda Y., Nakamura H., Yoshida K., et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci. 2003, 94:1034-1041.
21. Oliver J.A., Al-Awqati Q. An endothelial growth factor involved in rat renal development. J. Clin. Invest. 1998, 102:1208-1219.
22. Polyak K. Breast cancer: origins and evolution. J. Clin. Invest. 2007, 117:3155-3163.
23. Ren H., Tang X., Lee J.J., et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J. Clin. Oncol. 2004, 22:3230-3237.
24. Stierer M., Rosen H.R., Weber R., Marczell A., Kornek G.V., Czerwenka E. Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg. Gynecol. Obstet. 1992, 175:151-160.
25. Uyama H., Tomita Y., Nakamura H., et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin. Cancer Res. 2006, 12:6043-6048.
26. Yamamoto S., Tomita Y., Hoshida Y., et al. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin. Cancer Res. 2006, 12:117-122.
27. Yamamoto S., Tomita Y., Hoshida Y., et al. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann. Surg. Oncol. 2007, 14:2141-2149.
28. Yoshida K., Tomita Y., Okuda Y., et al. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann. Surg. Oncol. 2006, 13:159-167.